• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

多西他赛治疗转移性激素敏感型前列腺癌：急需降低中性粒细胞减少性发热风险。

Docetaxel for Metastatic Hormone-sensitive Prostate Cancer: Urgent Need to Minimize the Risk of Neutropenic Fever.

机构信息

Division of Hematology and Medical Oncology, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY.

Division of Hematology and Medical Oncology, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY.

出版信息

Eur Urol. 2016 Nov;70(5):707-708. doi: 10.1016/j.eururo.2016.06.041. Epub 2016 Jul 12.

DOI:10.1016/j.eururo.2016.06.041
PMID:27417033
Abstract

First-line docetaxel treatment for metastatic castration-sensitive prostate cancer is associated with higher rates of neutropenic fever compared with those with castration-resistant disease, and prophylactic granulocyte colony-stimulating factor should be considered in those harboring risk factors for developing neutropenia.

摘要

一线多西他赛治疗转移性去势敏感性前列腺癌与去势抵抗性疾病相比，中性粒细胞减少性发热的发生率更高，对于存在发生中性粒细胞减少风险因素的患者，应考虑预防性使用粒细胞集落刺激因子。

相似文献

1
Docetaxel for Metastatic Hormone-sensitive Prostate Cancer: Urgent Need to Minimize the Risk of Neutropenic Fever.多西他赛治疗转移性激素敏感型前列腺癌：急需降低中性粒细胞减少性发热风险。
Eur Urol. 2016 Nov;70(5):707-708. doi: 10.1016/j.eururo.2016.06.041. Epub 2016 Jul 12.
2
Safety and efficacy of 2-weekly cabazitaxel in metastatic castration-resistant prostate cancer.每两周一次卡巴他赛治疗转移性去势抵抗性前列腺癌的安全性和有效性
BJU Int. 2018 Feb;121(2):203-208. doi: 10.1111/bju.13855. Epub 2017 Apr 27.
3
Docetaxel-related toxicity in metastatic hormone-sensitive and metastatic castration-resistant prostate cancer.多西他赛在转移性激素敏感性和转移性去势抵抗性前列腺癌中的相关毒性
Med Oncol. 2016 Jul;33(7):77. doi: 10.1007/s12032-016-0793-1. Epub 2016 Jun 14.
4
Safety of cabazitaxel in senior adults with metastatic castration-resistant prostate cancer: results of the European compassionate-use programme.卡巴他赛治疗老年转移性去势抵抗性前列腺癌患者的安全性：欧洲同情用药项目的结果。
Eur J Cancer. 2014 Apr;50(6):1090-9. doi: 10.1016/j.ejca.2014.01.006. Epub 2014 Jan 31.
5
Risk factors for febrile neutropenia in patients receiving docetaxel chemotherapy for castration-resistant prostate cancer.接受多西他赛化疗的去势抵抗性前列腺癌患者发生发热性中性粒细胞减少的危险因素。
Support Care Cancer. 2014 Dec;22(12):3219-26. doi: 10.1007/s00520-014-2328-7. Epub 2014 Jul 5.
6
Intermittent Chemotherapy as a Platform for Testing Novel Agents in Patients With Metastatic Castration-Resistant Prostate Cancer: A Department of Defense Prostate Cancer Clinical Trials Consortium Randomized Phase II Trial of Intermittent Docetaxel With Prednisone With or Without Maintenance GM-CSF.间歇性化疗作为转移性去势抵抗性前列腺癌患者新型药物测试平台：美国国防部前列腺癌临床试验联盟多西他赛联合泼尼松间歇性给药联合或不联合维持性粒细胞巨噬细胞集落刺激因子的随机II期试验
Clin Genitourin Cancer. 2015 Jun;13(3):e191-8. doi: 10.1016/j.clgc.2014.12.004. Epub 2014 Dec 9.
7
Intermittent docetaxel chemotherapy as first-line treatment for metastatic castration-resistant prostate cancer patients.间歇性多西他赛化疗作为转移性去势抵抗性前列腺癌患者的一线治疗方法。
Future Oncol. 2015;11(6):965-73. doi: 10.2217/fon.14.284.
8
Taxanes in the management of metastatic castration-resistant prostate cancer: efficacy and management of toxicity.紫杉烷类药物在转移性去势抵抗性前列腺癌治疗中的应用：疗效与毒性管理
Crit Rev Oncol Hematol. 2014 Sep;91(3):248-56. doi: 10.1016/j.critrevonc.2014.02.003. Epub 2014 Feb 15.
9
Should docetaxel be administered earlier in prostate cancer therapy?多西他赛是否应在前列腺癌治疗中更早使用？
Expert Rev Anticancer Ther. 2015;15(9):977-9. doi: 10.1586/14737140.2015.1074042. Epub 2015 Jul 29.
10
Metastatic prostate cancer in 2015: The new and the old that is new again.2015年的转移性前列腺癌：新旧更替，旧貌换新颜。
Nat Rev Clin Oncol. 2016 Feb;13(2):73-4. doi: 10.1038/nrclinonc.2015.226. Epub 2015 Dec 31.

引用本文的文献

1
ATM/NEMO signaling modulates the expression of PD-L1 following docetaxel chemotherapy in prostate cancer.ATM/NEMO 信号转导调节多西他赛化疗后前列腺癌细胞程序性死亡配体 1 的表达。
J Immunother Cancer. 2021 Jul;9(7). doi: 10.1136/jitc-2020-001758.
2
Identification and characterization of biomarkers and their functions for docetaxel-resistant prostate cancer cells.多西他赛耐药前列腺癌细胞生物标志物的鉴定、特征及其功能
Oncol Lett. 2019 Sep;18(3):3236-3248. doi: 10.3892/ol.2019.10623. Epub 2019 Jul 16.
3
The timing of docetaxel initiation in metastatic castrate-sensitive prostate cancer and the rate of chemotherapy-induced toxicity.
多西他赛起始治疗转移性去势敏感性前列腺癌的时机和化疗诱导毒性的发生率。
Med Oncol. 2019 Jan 21;36(2):18. doi: 10.1007/s12032-018-1238-9.
4
PrLZ increases prostate cancer docetaxel resistance by inhibiting LKB1/AMPK-mediated autophagy.PrLZ 通过抑制 LKB1/AMPK 介导的自噬增加前列腺癌多西他赛耐药性。
Theranostics. 2018 Jan 1;8(1):109-123. doi: 10.7150/thno.20356. eCollection 2018.
5
Treatment of metastatic prostate cancer after STAMPEDE.STAMPEDE研究后转移性前列腺癌的治疗
Transl Androl Urol. 2017 Apr;6(2):315-316. doi: 10.21037/tau.2017.02.01.